Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 DoseRanging Study

被引：0

作者：

Maurer, Marcus ^{[1
]}

Gimenez-Arnau, Ana ^{[2
]}

Ferrucci, Silvia ^{[3
]}

Mikol, Vincent ^{[4
]}

Sun, Iris ^{[5
]}

Mannent, Leda ^{[4
]}

Gereige, Jessica ^{[6
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Univ Pompeu Fabra, Hosp Mar & Res Inst, Barcelona, Spain

[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Dermatol, Milan, Italy

[4] Sanofi, Chilly Mazarin, France

[5] Sanofi, Beijing, Peoples R China

[6] Sanofi, Cambridge, MA USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

L38

引用

页码：AB373 / AB373

页数：1

共 50 条

[1] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
Rui, Wenlong
Li, Xia
Zheng, Jie
Pan, Weili
Zheng, Min
Lu, Yan
Li, Fuqiu
Ding, Yangfeng
Zhang, Jianzhong
Li, Hongying
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
[2] Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
Tanaka, Yoshiya
Takeuchi, Tsutomu
Yamanaka, Hisashi
Nakamura, Hiroyuki
Toyoizumi, Shigeyuki
Zwillich, Samuel
MODERN RHEUMATOLOGY, 2015, 25 (04) : 514 - 521
[3] Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase3 Pivotal Trials
Ensina, Luis Felipe
Bernstein, Jonathan
Sussman, Gordon
Maurer, Marcus
Gimenez-Arnau, Ana Maria
Saini, Sarabjit
Varanasi, Vineeth
Barve, Avantika
Hua, Eva
Patekar, Manmath
Severin, Thomas
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB130 - AB130
[4] Efficacy and safety of omalizumab in Japanese and Korean patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): Results from the phase III POLARIS study
Hide, Michihiro
Park, Hae-Sim
Igarashi, Atsuyuki
Ye, Young Min
Kim, Tae-Bum
Yagami, Akiko
Lee, Jae-Hyun
Fukunaga, Atsushi
Khalil, Sam
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB112 - AB112
[5] Safety and tolerability of omalizumab in patients with chronic idiopathic/spontaneous urticaria: Results from the OPTIMA study
Sussman, Gordon
Hebert, Jacques
Gooderham, Melinda
Gulliver, Wayne
Lynde, Charles W.
Papp, Kim A.
Yang, William H.
de Takacsy, Frederica
Chambenoit, Olivier
Rihakova, Lenka
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB250 - AB250
[6] Ziprasidone efficacy and safety in acute bipolar mania: 12-week study
Ramey, TS
Giller, EL
Riesenberg, R
Trivedi, JK
BIPOLAR DISORDERS, 2005, 7 : 89 - 89
[7] Ziprasidone efficacy and safety in acute bipolar mania: 12-week study
Ramey, TS
Murray, S
Giller, E
English, P
Riesenberg, R
Trivedi, J
Tochilov, VA
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S441 - S441
[8] Long-term treatment with remibrutinib shows favourable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week Phase 2b extension study
Gimenez-Arnau, A. M.
Tillinghast, J.
Jain, V.
Haemmerle, S.
Lheritier, K.
Walsh, P.
Hugot, S.
Wells, M.
Zharkov, A.
Carr, W.
ALLERGY, 2023, 78 : 244 - 245
[9] Safety results from a 12-week open-label, multicenter study of sodium oxybate in patients with narcolepsy
Mamelak, M.
Swick, T.
Emsellem, H.
Montplaisir, J.
Lai, C.
Black, J.
JOURNAL OF SLEEP RESEARCH, 2014, 23 : 289 - 289
[10] Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
McGarvey, Lorcan
Morice, Alyn H.
Smith, Jaclyn
Sher, Mandel
Vaezi, Michael
Guilleminault, Laurent
Niimi, Akio
Roth, Katrin
Saarinen, Riitta
Pires, Philippe Vieira
Wosnitza, Melanie
Dicpinigaitis, Peter
EUROPEAN RESPIRATORY JOURNAL, 2021, 58

← 1 2 3 4 5 →